Novel Strategies for the Prevention of Bypass Graft Failure

BioDrugs

Volumn 18, Issue 1, 2004, Pages 1-8

  Mann, Michael J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTISENSE OLIGODEOXYNUCLEOTIDE; CELL CYCLE PROTEIN; CYCLINE; FIBROBLAST GROWTH FACTOR 2; LENTIVIRUS VECTOR; PARVOVIRUS VECTOR; PLASMID VECTOR; POLYESTER; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR E2F1; VASCULAR CELL ADHESION MOLECULE 1; VIRUS VECTOR;

ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; BYPASS SURGERY; CELL CYCLE G1 PHASE; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; DNA SYNTHESIS; ENDOTHELIUM CELL; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC ENGINEERING; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; GRAFT FAILURE; HERPES SIMPLEX VIRUS VECTOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 VECTOR; INFLAMMATION; ISCHEMIA; ISCHEMIC HEART DISEASE; MOLECULAR BIOLOGY; PRIORITY JOURNAL; REPERFUSION INJURY; REVASCULARIZATION; REVIEW; SMOOTH MUSCLE FIBER; STENT; THROMBOSIS; VEIN GRAFT; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CORONARY ARTERY BYPASS; GENE THERAPY; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS;

EID: 1242341394     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200418010-00001     Document Type: Review

References (55)

1. Fitzgibbon GM, Kafka HP, Leach AJ, et al. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5065 grafts related to survival and reoperation in 1388 patients during 25 years. J Am Coll Cardiol 1996; 28: 616-26
2. Campeau L, Enjalbert M, Lesperance J, et al. The relation of risk factors to the development of atherosclerosis in saphenous vein bypass grafts and the progression of disease in the native circulation: a study 10 years after aortocoronary bypass surgery. N Engl J Med 1984; 311: 1329-34
3. Grondin CM. Late results of coronary artery grafting: is there a flag on the field? J Thorac Cardiovasc Surg 1984; 87: 161-6
4. Reardon MJ, Conklin LD, Reardon PR, et al. Coronary artery bypass conduits: review of current status. J Cardiovasc Surg 1997; 97: 916-31
5. Campeau L. Lipid lowering and coronary bypass graft surgery. Curr Opin Cardiol 2000; 15: 395-9
6. Clowes AW, Reidy MA. Prevention of stenosis after vascular reconstruction: pharmacologic control of intimal hyperplasia. J Vasc Surg 1991; 13: 885-90
7. Cox JL, Chaisson DA, Gotleib AI. Stranger in a strange land: the pathogeneis of saphenous vein graft stenosis. Prog Cardiovasc Dis 1991; 34: 45-68
8. Kohler TR, Kirkman TR, Gordon D, et al. Mechanism of long-term degeneration of arterialized vein grafts. Am J Surg 1990; 160: 257-61
9. Clinton SK, Libby P. Cytokines and growth factors in atherogenesis. Arch Pathol Lab Med 1992; 116: 1292-300
10. Faries PL, Marin ML, Veith FJ, et al. Immunolocalization and temporal distribution of cytokine expression during the development of vein graft intimai hyperplasia in an experimental model. J Vasc Surg 1996; 24: 463-71
11. Hoch JR, Stark VK, Hullett DA, et al. Vein graft intimal hyperplasia: leukocytes and cytokine expression. Surgery 1994; 116: 463-71
12. Zwolak RM, Adams MC, Clowes AW. Kinetics of vein graft hyperplasia: association with tangential stress. J Vasc Surg 1987; 5: 126-36
13. Tanaka H, Sukhova GK, Swanson SJ, et al. Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury. Circulation 1993; 88: 1788-803
14. Loppnow H, Libby P. Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. J Clin Invest 1990; 85: 731-8
15. Galis ZS, Muszynski M, Sukhova GK, et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 1994; 75: 181-9
16. Chester AH, O'Neil GS, Moncada S, et al. Low basal and stimulated release of nitric oxide in atherosclerotic epicardial coronary arteries. Lancet 1990; 336: 897-900
17. Bossaller C, Habib GB, Yamamoto H, et al. Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5′-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta. J Clin Invest 1987; 79: 170-4
18. Ku DD, Caulfield JB, Kirklin JK. Endothelium-dependent responses in long-term human coronary artery bypass grafts. Circulation 1991; 83: 402-11
19. Weidinger FF, McLenachan JM, Cybulsky M, et al. Persistent dysfunction of regenerated endothelium following balloon angioplasty of rabbit iliac artery. Circulation 1990; 81: 1667-79
20. Park TC, Harker CT, Edwards JM, et al. Human saphenous vein grafts explanted from the arterial circulation demonstrate altered smooth-muscle and endothelial responses. J Vasc Surg 1993; 18: 61-9
21. Cross KS, El-Sanadiki MN, Murray JJ, et al. Functional abnormalities of experimental autologous vein graft neoendothelium. Ann Surg 1988; 208: 631-8
22. Braun-Dullaeus RC, Mann MJ, Dzau VJ. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation 1998 Jul 7; 98 (1): 82-9
23. Zwolak RM, Kirkman TR, Clowes AW. Atherosclerosis in rabbit vein grafts. Arteriosclerosis 1989; 9: 374-9
24. Conte MS, Mann MJ, Simosa HF, et al. Genetic interventions for vein bypass graft disease: a review. J Vasc Surg 2002 Nov; 36 (5): 1040-52
25. Colman A. Antisense strategies in cell and developmental biology. J Cell Sci 1990; 97: 399-409
26. Hannon GJ. RNA interference. Nature 2002; 418: 244-51
27. Zaug A, Been M, Cech T. The tetrahymena ribozyme acts like an RNA restriction endonuclease. Nature 1986; 324: 429-33
28. Bielinska A, Schivdasani RA, Zhang L, et al. Regulation of gene expression with double-stranded phosphothioate oligonucleotides. Science 1990; 250: 997-1000
29. Morishita R, Gibbons GH, Ellison KE, et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci U S A 1993; 90: 8474-8
30. Mann MJ, Gibbons GH, Kernoff RS, et al. Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci U S A 1995; 92: 4502-6
31. Gaubatz S, Wood JG, Livingston DM. Unusual proliferation arrest and transcriptional control properties of a newly discovered E2F family member, E2F-6. Proc Natl Acad Sci U S A 1998; 95: 9190-5
32. Morishita R, Gibbons GH, Horiuchi M, et al. A novel molecular strategy using cis element 'decoy' of E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci U S A 1995; 92: 5855-9
33. Ehsan A, Mann MJ, Dell'Acqua G, et al. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J Thorac Cardiovasc Surg 2001; 121: 714-22
34. Mann MJ, Gibbons GH, Tsao PS, et al. Cell cycle inhibition preserves endothelial function in genetically engineered vein grafts. J Clin Invest 1997; 99: 1295-301
35. Mann MJ, Whittemore AD, Donaldson MC, et al. Ex vivo gene therapy for human bypass vein grafts: the PREVENT single centre randomised clinical trial. Lancet 1999; 354: 1493-8
36. Mann MJ, Gibbons GH, Poston R, et al. Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. Proc Natl Acad Sci U S A 1999; 96: 6411-6
37. Grube E, Felderhoff T, Fitzgerald PJ, et al. Genetic manipulation of human coronary artery bypass grafts with E2F decoy (GT003) reduces clinical graft failure: results of the randomized, controlled PREVENT II trial. Late-breaking Clinical Trials Session, American Heart Association Scientific Sessions; 2001 Nov 12; Anaheim, California
38. Chen S-J, Wilson JM, Muller DWM. Adenovirus-mediated gene transfer of soluble vascular cell adhesion molecule to porcine interposition vein grafts. Circulation 1994; 89: 1922-8
39. Chiu-Pinheiro CK, O'Brien T, Katusic ZS, et al. Gene transfer to coronary artery bypass conduits. Ann Thorac Surg 2002; 74: 1161-6
40. Skelly CL, Curi MA, Meyerson SL, et al. Prevention of restenosis by a herpes simplex virus mutant capable of controlled long-term expression in vascular tissue in vivo. Gene Ther 2001; 8: 1840-6
41. Kupfer JM, Ruan XM, Liu G, et al. High efficiency gene transfer to autologous rabbit jugular vein grafts using adenovirus-transferrin/polylysine- DNA complexes. Hum Gene Ther 1994; 5: 1437-43
42. George SJ, Johnson JL, Angelini GD, et al. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. Hum Gene Ther 1998; 9: 867-77
43. George SJ, Baker AH, Angelini GD, et al. Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins. Gene Ther 1998; 5 (11): 1552-60
44. George SJ, Lloyd CT, Angelini GD, et al. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated over-expression of tissue inhibitor of metalloproteinase-3. Circulation 2000; 101: 296-304
45. Bai H, Morishita R, Kida I, et al. Inhibition of intimal hyperplasia after vein grafting by in vivo transfer of human senescent cell-derived inhibitor-1 gene. Gene Ther 1998; 5 (6): 761-9
46. Ohno N, Itoh H, Ikeda T, et al. Accelerated reendothelialization with suppressed thrombogenic property and neointimal hyperplasia of rabbit jugular vein grafts by adenovirus-mediated gene transfer of C-type natriuretic peptide. Circulation 2002; 105: 1623-6
47. Ohta S, Komori K, Yonemitsu Y, et al. Intraluminal gene transfer of endothelial cell-nitric oxide synthase suppresses intimai hyperplasia of vein grafts in cholesterol-fed rabbit: a limited biological effect as a result of the loss of medial smooth muscle cells. Surgery 2002; 131: 644-53
48. Kibbe MR, Tzeng E, Gleixner SL, et al. Adenovirus-mediated gene transfer of human inducible nitric oxide synthase in porcine vein grafts inhibits intimal hyperplasia. J Vasc Surg 2001; 34: 156-65
49. Curi MA, Skelly CL, Meyerson SL, et al. Sustained inhibition of experimental neointimal hyperplasia with a genetically modified herpes simplex virus. J Vasc Surg 2003 Jun; 37 (6): 1294-300
50. Mayr U, Mayr M, Li C, et al. Loss of p53 accelerates neointimal lesions of vein bypass grafts in mice. Circ Res 2002; 90: 197-204
51. Pollman MJ, Hall JL, Mann MJ, et al. Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease. Nat Med 1998; 4: 222-7
52. Shoji T, Yonemitsu Y, Komori K, et al. Intramuscular gene transfer of FGF-2 attenuates endothelial dysfunction and inhibits intimal hyperplasia of vein grafts in poor-runoff limbs of rabbit. Am J Physiol Heart Circ Physiol 2003 Jul; 285 (1): H173-82
53. Shintani T, Sawa Y, Takahashi T, et al. Intraoperative transfection of vein grafts with the NFkappaB decoy in a canine aortocoronary bypass model: a strategy to attenuate intimal hyperplasia. Ann Thorac Surg 2002 Oct; 74 (4): 1132-7
54. Angelini GD, Lloyd C, Bush R, et al. An external, oversized, porous polyester stent reduces vein graft neointima formation, cholesterol concentration, and vascular cell adhesion molecule 1 expression in cholesterol-fed pigs. J Thorac Cardiovasc Surg 2002 Nov; 124 (5): 950-6
55. Huynh TT, Davies MG, Thompson MA, et al. Local treatment with recombinant tissue factor pathway inhibitor reduces the development of intimal hyperplasia in experimental vein grafts. J Vasc Surg 2001 Feb; 33 (2): 400-7